Pharmacological Effects of Zotepine and other Antipsychotics on the Central 5-HT2 Receptors

The effects of the atypical neuroleptic zotepine in comparison with clozapine, risperidone and haloperidol were examined in tests related to the central 5-HT2 activity. Zotepine, as well as clozapine and risperidone, were very potent inhibitors of the 5-HTP-induced head twitches (the behavior mediated by 5-HT2 receptors) in mice, with rank order of potency risperidone > zotepine > clozapine; haloperidol used in high doses only slightly reduced the effect of 5-HTP. Zotepine, clozapine, risperidone and haloperidol antagonized the stimulatory effects of mCPP on the hind limb flexor reflex in spinal rats. As the mCPP-induced stimulation is considered to be mediated by 5-HT2 receptors, the above results provide further evidence for the 5-HT2 antagonistic activity of the drugs studied. Te rank order of potency in that test was the same as in the 5-HTP-induced head twitches (risperidone > zotepine > clozapine). The effect of haloperidol was somewhat unspecific, since its active doses were very high. In the model of hind limb flexor reflex of spinal rats, the anti-alpha 2-adrenergic effect was also tested. Clonidine-induced stimulation of the hind limb flexor reflex (an alpha 2-adrenergic effect) was antagonized by zotepine, clozapine, risperidone and haloperidol. It may be concluded that zotepine, clozapine and risperidone show an alpha 2-adrenergic antagonistic activity (order of potency: zotepine = risperidone > clozapine). The effect of haloperidol may be considered unspecific, since it is observed at high (cataleptic) doses only. In conclusion, it appears that zotepine, as well as clozapine and risperidone, are strong 5-HT2 antagonists, while haloperidol is not.

[1]  G. Skuza,et al.  Effects of zotepine on the central 5-HT receptor subpopulations , 1992, European Neuropsychopharmacology.

[2]  R. Heel,et al.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. , 1990, Drugs.

[3]  P. Janssen,et al.  Pilot Clinical Investigation of Risperidone in the Treatment of Psychotic Patients , 1990, Pharmacopsychiatry.

[4]  A. Megens,et al.  Behavioral disinhibition after risperidone in amphetamine challenged rats: a comparison with haloperidol , 1990 .

[5]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[6]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[7]  S. Yamawaki Profiles of Clinical Efficacy and Pharmacological Action of Zotepine , 1987, Pharmacopsychiatry.

[8]  H. Hinterhuber,et al.  Zotepine in the Treatment of Negative Symptoms in Chronic Schizophrenia , 1987, Pharmacopsychiatry.

[9]  A. Puech,et al.  Classification of Neuroleptics - Zotepine , 1987, Pharmacopsychiatry.

[10]  M. Ackenheil,et al.  Zotepine, a Neuroleptic Drug with a Bipolar Therapeutic Profile , 1987, Pharmacopsychiatry.

[11]  Y. Nomura,et al.  Effects of zotepine, chlorpromazine and haloperidol on D-1, D-2, D-3 and D-4 subtypes of dopamine receptors in rat striatal and bovine caudate nucleus membranes , 1986, Neurochemistry International.

[12]  S. Marder,et al.  Akathisia with haloperidol and thiothixene. , 1984, Psychopharmacology bulletin.

[13]  P. Janssen,et al.  The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: Antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist , 1983, Neuropharmacology.

[14]  T. Crow Positive and Negative Schizophrenic Symptoms and the Role of Dopamine , 1980, British Journal of Psychiatry.

[15]  R. Neuman,et al.  Facilitation of spinal motoneurone excitability by 5-hydroxytryptamine and noradrenaline , 1980, Brain Research.

[16]  G. Skuza,et al.  The influence of neuroleptics on the behavioural effect of 5-hydroxytryptophan. , 1978, Polish journal of pharmacology and pharmacy.

[17]  B. Przewłocka,et al.  Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy , 1975, Pharmacology Biochemistry and Behavior.

[18]  W. Feuerlein,et al.  [Drug addiction and drug abuse]. , 1969, Munchener medizinische Wochenschrift.

[19]  S. Corne,et al.  A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. , 1963, British journal of pharmacology and chemotherapy.

[20]  A. Megens,et al.  Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). , 1992, The Journal of pharmacology and experimental therapeutics.

[21]  S. Kanba,et al.  Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain. , 1991, The Japanese journal of psychiatry and neurology.

[22]  R. Glennon,et al.  Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents. , 1991, Life sciences.

[23]  C. Niemegeers,et al.  Serotonin Involvement in the Action of Antipsychotic Drugs , 1990 .

[24]  S. Otsuki,et al.  Antimanic effect of zotepine. , 1986, Clinical therapeutics.

[25]  S. Marini,et al.  Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent , 1986 .

[26]  H. Satoh,et al.  Effect of zotepine on fenfluramine-induced hyperthermia in rats. , 1984, Japanese Journal of Pharmacology.

[27]  T. Yamamoto,et al.  Effect of zotepine on head-twitch induced by L-5-hydroxytryptophan, mescaline and 2,5-dimethoxy-4-methylamphetamine in mice and rats. , 1983, Japanese Journal of Pharmacology.

[28]  S. Katsuki,et al.  The central anti-serotonin activity of zotepine, a new neuroleptic, in rats. , 1982, Japanese journal of pharmacology.

[29]  Y. Satoh,et al.  Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug. , 1979, Arzneimittel-Forschung.

[30]  J. Maj,et al.  Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy. , 1976, Archivum immunologiae et therapiae experimentalis.

[31]  S. Stahl,et al.  The dopamine hypothesis of schizophrenia: a review. , 1976, Schizophrenia bulletin.